{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-023044","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.199888+00:00","generated_at":"2026-06-25T02:16:06.532736+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LENSAR receives FDA 510(k) clearance for ALLY Adaptive Cataract Treatment System","bullets":["FDA 510(k) clearance received on June 9, 2022 for next-generation ALLY system.","ALLY is first FDA-cleared platform for femtosecond-laser cataract surgery in a single sterile environment.","Initial controlled launch planned for Q3 2022; wider availability targeted in 2023.","Over 125 surgeons experienced ALLY during live demonstrations at ASRS and company office."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-023044","json":"https://secwatch.observer/filing/0001564590-22-023044.json","markdown":"https://secwatch.observer/filing/0001564590-22-023044.md","text":"https://secwatch.observer/filing/0001564590-22-023044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022023044/0001564590-22-023044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022023044/lnsr-8k_20220609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:16:06.532736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}